September 21, 2026
| Trial | EIK1001-006 |
|---|---|
| Cancer Type | Melanoma |
| Hospital(s) | Belfast City Hospital |
| Information | A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) |
| Trial Open | Yes |